Activation of PXR causes drug interactions with Paxlovid in transgenic mice
Acta Pharmaceutica Sinica B, 2023 Paxlovid is a nirmatrelvir (NMV) and ritonavir (RTV) co-packaged medication used for the treatment of coronavirus disease 2019 (COVID-19). The active component of Paxlovid is NMV and RTV is a pharmacokinetic booster.
Saifei Lei +6 more
doaj +1 more source
Severe COVID-19 following Rituximab and Nirmatrelvir/ritonavir treatment in a patient with MCTD, Case Report [PDF]
, 2023 This is an article about how the use of medications such as nirmatrelvir/ritonavir can cause rebound COVID-19 and how the use of Rituximab, a biologic agent, can prolong the duration and increase severity of symptoms of COVID-19 in patients with pre ...
Baig, Rohail A +5 more
core +2 more sources
The Public Health Impact of Paxlovid COVID-19 Treatment in the United States [PDF]
, 2023 The antiviral drug Paxlovid has been shown to rapidly reduce viral load. Coupled with vaccination, timely administration of safe and effective antivirals could provide a path towards managing COVID-19 without restrictive non-pharmaceutical measures. Here,
Bai, Yuan +9 more
core +2 more sources
Journal of Translational Medicine, 2022 Background The COVID-19 pandemic has become a huge threat to human health, infecting millions of people worldwide and causing enormous economic losses.
Keyu Kong +10 more
doaj +1 more source
Posterior Reversible Encephalopathy Syndrome in an Older Patient in the COVID-19 and Paxlovid Era
Annals of Internal Medicine: Clinical Cases, 2023 Nirmatrelvir/ritonavir (Paxlovid) has been prescribed increasingly for treatment of COVID-19. Due to ritonavir's inhibition of CYP3A4, there are many medication interactions to consider.
Katharine Rosiene +4 more
doaj +1 more source
Safety and Efficacy of Paxlovid in COVID-19 Treatment: A Rapid Review
Health Technology Assessment in Action, 2022 Context: In the first stage of viral replication, COVID-19 may cause a remarkable inflammatory response in patients. Paxlovid is an oral antivirus medicine that functions through the inhibition of one of the essential enzymes to viral replication, called
Mohamad Reza Mobinizadeh +8 more
doaj +1 more source
Paxlovid-Induced Symptomatic Bradycardia and Syncope
Cureus, 2023 Paxlovid (nirmatrelvir/ritonavir) is a game changer in the fight against COVID-19 due to its ease of administration and significant benefits of reducing progression to severe COVID-19, hospitalization, and death. Cardiac adverse events such as bradycardia and syncope are not known with this medication.
Ganipisetti, Venu M +2 more
openaire +2 more sources
Trends, variation, and clinical characteristics of recipients of antiviral drugs and neutralising monoclonal antibodies for covid-19 in community settings: retrospective, descriptive cohort study of 23.4 million people in OpenSAFELY [PDF]
, 2023 Objective: To ascertain patient eligibility status and describe coverage of antiviral drugs and neutralising monoclonal antibodies (nMAB) as treatment for covid-19 in community settings in England.
Andrews, Colm D +41 more
core +2 more sources
Ranolazine Toxicity Secondary to Paxlovid
Cureus, 2023 An Emergency Use Authorization (EUA) was issued by the FDA on December 22, 2021 for the investigational antiviral drug nirmatrelvir copackaged with the HIV-1 protease inhibitor ritonavir (Paxlovid - Pfizer) for outpatient treatment of mild to moderate COVID-19 in children 12 years and old that are high risk of severe disease.
Casey, Bradley +4 more
openaire +2 more sources
Frontiers in Psychiatry, 2022 BackgroundSchizophrenia is considered one of the major risk factors for mortality from SARS-CoV-2 infection. Early antiviral treatment is important to decrease the risk of mortality.
Chun-I Liu +6 more
doaj +1 more source